FDA Nominee Faces Calls to Strengthen Rare Disease Drug Approval Pathways
Dr. Heidi Overton, President Trump's nominee to lead the FDA, identified rare-disease treatments as a "key priority" during her confirmation hearing. The agency is simultaneously negotiating PDUFA VIII, a five-year funding and drug-review agreement that will shape its regulatory approach. Rare disease patients wait an average of five to six years and consult seven to eight doctors before receiving an accurate diagnosis.
Single source · Not corroborated
Dr. Heidi Overton's confirmation hearing placed rare diseases at the center of the FDA's near-term agenda, and advocates are urging new leadership to translate that stated priority into concrete regulatory policy. The Washington Examiner published a commentary by David Gusick, who works with rare disease patients and families, arguing that the agency must provide clearer and more efficient approval pathways while preserving rigorous safety and efficacy standards.
Gusick described the diagnostic burden facing patients with rare diseases — an average five-to-six-year wait across seven to eight physicians before a confirmed diagnosis. In AL amyloidosis, a rare disease in which the immune system attacks the body, the median delay to diagnosis is approximately two years, by which time irreversible organ damage to the heart and kidneys may already have occurred. He argued that for patients with rapidly progressing conditions, each month of regulatory uncertainty carries direct clinical consequences.
A central policy concern raised in the piece involves single-arm trials — clinical studies conducted without a randomized control group. For decades, single-arm trials were a standard approval route for rare, rapidly progressing diseases where assigning patients to a placebo or an inferior treatment would be impractical or unethical. Last year, comments attributed to the FDA's Center for Biologics Evaluation and Research raised doubts about whether single-arm data would continue to meet the evidentiary bar for rare-disease approvals. FDA leadership subsequently stated that those comments do not reflect official policy, but Gusick reported that drug developers still lack definitive guidance as they design trials.